Genomic profiling of prostate cancers from African American men 1

Neoplasia

Volumn 11, Issue 3, 2009, Pages 305-312

  Castro, Patricia ^a,b   Creighton, Chad J ^a   Ozen, Mustafa ^a,b,c   Bcrel, Dror ^a   Mims, Martha P ^a   Ittmann, Michael ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c YEDITEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AFRICAN AMERICAN; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CLINICAL ARTICLE; COMPARATIVE STUDY; DNA FINGERPRINTING; EUROPEAN AMERICAN; GENE LOCUS; GENE LOSS; GENE MAPPING; GENE NUMBER; HUMAN; HUMAN TISSUE; MALE; MICROARRAY ANALYSIS; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 62549110050     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.81530     Document Type: Article

References (40)

1. Freedland SJ and Isaacs WB (2005). Explaining racial differences in prostate cancer in the United States: sociology or biology? Prostate 62, 243-252.
2. Robbins AS, Whittemore AS, and Thom DH (2000). Differences in socioeconomic status and survival among white and black men with prostate cancer.Am J Epidemiol 151, 409-416.
3. Evans S, Metcalfe C, Ibrahim F, Persad R, and Ben-Shlomo Y (2008). Investigating black-white differences in prostate cancer prognosis: a systematic review and meta-analysis. Int J Cancer 123, 430-435.
4. Sun J, Liu W, Adams TS, Sun J, Li X, Turner AR, Chang B, Kim JW, Zheng SL, Isaacs WB, et al. (2007). DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies. Prostate 67, 692-700.
5. Kim JH, Dhanasekaran SM, Mehra R, Tomlins SA, Gu W, Yu J, Kumar-Sinha C, Cao X, Dash A, Wang L, et al. (2007). Integrative analysis of genomic aberrations associated with prostate cancer progression. Cancer Res 67, 8229-8239.
6. Jiang M, Li M, Fu X, Huang Y, Qian H, Sun R, Mao Y, Xie Y, and Li Y (2008). Simultaneously detection of genomic and expression alterations in prostate cancer using cDNA microarray. Prostate 68, 1496-1509.
7. Lapointe J, Li C, Giacomini CP Salari K, Huang S, Wang P Ferrari M, Hernandez-Boussard T, Brooks JD, and Pollack JR (2007). Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res 67, 8504-8510.
8. Dumur CI, Dechsukhum C, Ware JL, Cofreld SS, Best AM, Wilkinson DS, Garrett CT, and Ferreira-Gonzalez A (2003). Genome-wide detection of LOH in prostate cancer using human SNP microarray technology. Genomics 81, 260-269.
9. Lieberfarb ME, Lin M, Lechpammer M, Li C, Tanenbaum DM, Febbo PG, Wright RL, Shim J, Kantoff PW, Loda M, et al. (2003). Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP. Cancer Res 63, 4781-4785.
10. Liu W, Chang B, Sauvageot J, Dimitrov L, Gielzak M, Li T, Yan G, Sun J, Sun J, Adams TS, et al. (2006). Comprehensive assessment of DNA copy number alterations in human prostate cancers using Affymetrix 100K SNP mapping array. Genes Chromosomes Cancer AS, 1018-1032.
11. Tørring N, Borre M, Sorensen KD, Andersen CL, Wiuf C, and Ørntoft TF (2007). Genome-wide analysis of allelic imbalance in prostate cancer using the Affymetrix 50K SNP mapping array. Br J Cancer 96, 499-506.
12. Cher ML, Lewis PE, Banerjee M, Hurley PM, Sakr W, Grignon DJ, and Powell IJ (1998). A similar pattern of chromosomal alterations in prostate cancers from African-Americans and Caucasian Americans. Clin Cancer Res 4, 1273-1278.
13. Bentz M, Plesch A, Stilgenbauer S, Dohner H, and Lichter P (1998). Minimal sizes of deletions detected by comparative genomic hybridization. Genes Chromosomes Cancer 21, 172-175.
14. Ittmann M, Wieczorek R, Heller P, Dave A, Provet J, and Krolewski J (1994). Alterations in the p53 and MDM-2 genes are infrequent in clinically localized, stage B prostate adenocarcinomas. Am J Pathol 145, 287-293.
15. Li C and Wong WH (2001). Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA 98, 31-36.
16. Eisen MB, Spellman PT, Brown PO, and Botstein D (1998). Clustet analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95, 14863-14868.
17. Saldanha AJ (2004). Java Treeview-extensible visualization of microarray data. Bioinformatics 20, 3246-3248.
18. Betgamaschi A, Kim Y, Wang P, Sorlie T, Hernadez-Boussard T Lonning P, Tibshirani R, Borresen A, and Pollack J (2006). Distinct patterns of DNA copynumber alteration are associated with different clinicopathological features and gene-expression subtypes ofbreast cancer. Genes Chromosome Cancer 45, 1033-1040.
19. Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, Lin WM, Province MA, Kraja A, Johnson LA, et al. (2007). Characterizing the cancer genome in lung adenocarcinoma. Nature 450, 893-898.
20. Gibbs M, Stanford JL, Mclndoe RA, Jarvik GP, Kolb S, Goode EL, Chakrabarti L, Schuster EF, Buckley VA, Miller EL, et al. (1999). Evidence for a rare prostate cancer-susceptibility locus at chromosome lp36. Am J Hum Genet 64, 776-787.
21. Xu J, Gillanders EM, Isaacs SD, Chang BL, Wiley KE, Zheng SL, Jones M, Gildea D, Riedesel E, Albertus J, et al. (2003). Genome-wide scan for prostate cancer susceptibility genes in the Johns Hopkins heteditary prostate cancer families. Prostate 57, 320-325.
22. Witte JS, Suarez BK, Thiel B, Lin J, Yu A, Banerjee TK, Burmester JK, Casey G, and Catalona WJ (2003). Genome-wide scan of brothers: replication and fine mapping of prostate cancer susceptibility and aggressiveness loci. Prostate 57, 298-308.
23. Lange EM, Robbins CM, Gillanders EM, Zheng SL, Xu J, Wang Y, White KA, Chang BL, Ho LA, Trent JM, et al. (2007). Fine-mapping the putative chromosome 17q21-22 prostate cancer susceptibility gene to a 10 cM region based on linkage analysis. Hum Genet 121, 49-55.
24. Kammerer S, Roth RB, Reneland R, Marnellos G, Hoyal CR, Markward NJ, Ebner F, Kiechle M, Schwarz-Boeger U, Griffiths LR, et al. (2004). Large-scale association study identifies ICAM gene region as breast and prostate cancer susceptibility locus. Cancer Res 64, 8906-8910.
25. Ittmann M (1996). Allelic loss on chromosome 10 in prostate adenocarcinoma. Cancer Res 56, 2143-2147.
26. Melamed J, Einhorn JM, and Ittmann M (1997). Allelic loss on chromosome 13q in human prostate carcinoma. Clin Cancer Res 3, 1867-1872.
27. Fukuhara H, Maruyama T, Nomura S, Oshimura M, Kitamura T, Sekiya T, and Murakami Y (2001). Functional evidence for the presence of tumor suppressor gene on chromosome 10pl5 in human prostate cancers. Oncogene 20, 314-319.
28. Gao AC, Lou W, Ichikawa T, Denmeade SR, Barrett JC, and Isaacs JT (1999). Suppression of the tumorigenicity of prostatic cancer cells by gene(s) located on human chromosome 19pl3.1-13.2. Prostate 38, 46-54.
29. Freedman ML, Haiman CA, Patterson N, McDonald GJ, Tandon A, Waliszewska A, Penney K, Steen RG, Ardlie K, John EM, et al. (2006). Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci USA 103, 14068-14073.
30. Shivapurkar N, Maitra A, Milchgrub S, and Gazdar AF (2001). Deletions of chromosome 4 occur early during the pathogenesis of colorectal carcinoma. Hum Pathol 32, 169-177.
31. Sibley K, Bell S, and Knowles MA (2000). Redefining a critical region of LOH on 4pl6.3 in bladder cancer. Genes Chromosomes Cancer 29, 378-379.
32. Shivapurkar N, Sood S, Wistuba II, Virmani AK, Maitra A, Milchgrub S, Minna JD, and Gazdar AF (1999). Multiple regions of chromosome 4 demonstrating allelic losses in breast carcinomas. Cancer Res 59, 3576-3580.
33. Marcotte R, Chen JM, Huard S, and Wang E (2005). c-Myc creates an activation loop by transcriptionally repressing its own functional inhibitor, hMad4, in young fibroblasts, a loop lost in teplicatively senescent fibroblasts. J Cell Biochem 96, 1071-1085.
34. Talukder AH, Meng Q, and Kumar R (2006). CRIPak, a novel endogenous Pakl inhibitor. Oncogene 25, 1311-1319.
35. Sastry KS, Karpova Y, and Kulik G (2006). Epidermal growth factor protects prostate cancer cells from apoptosis by inducing BAD phosphorylation via redundant signaling pathways. J Biol Chem 281, 27367-27377.
36. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W Bergerheim U, et al. (2004). Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 101, 811-816.
37. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, et al. (2005). Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644-648.
38. Wang J, Cai Y, Ren C, and Ittmann M (2006). Expression of variant TMPRSS2/ ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 66, 8347-8351.
39. Narod SA, Seth A, and Nam R (2008). Fusion in the ETS gene family and prostate cancer. Br J Cancer 99, 847-851.
40. Wang J, Cai Y, Yu W, Ren C, Spencer DM, and Ittmann M (2008). Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res 68, 8516-8524.